RightFit
RecruitingPhase not listed

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: MRI scans, CT scans

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "The purpose of this research study is to evaluate the structure and function of the brain in healthy aging and early Alzheimer's disease using positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) imaging."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks for signs that Alzheimer’s disease is changing from having no symptoms to having symptoms. It is for adults with normal memory and thinking or early Alzheimer’s symptoms who take part in certain Washington University research projects.

To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be older than 18. People of any sex or race may join.
  • Take part in an ongoing project linked to the Knight Alzheimer Disease Research Center (ADRC) at Washington University.
  • Be referred by MAP staff and a Washington University doctor.
  • Have normal memory and thinking or early Alzheimer’s symptoms.
  • Be willing and able to complete the study procedures.
  • Be able to understand and agree to join the study and follow its procedures.

Who can't join

  • Have a condition that the study doctor believes could make the study risky, make procedures hard to handle, or affect the study data.
  • Have an allergy to AV-1451, PIB, or any of their ingredients.
  • Cannot safely have PET, CT, or MRI scans, which take pictures inside the body. Reasons may include electronic medical devices or trouble lying still for a long time.
  • Have a severe fear of tight or closed spaces.
  • Be pregnant or breastfeeding. Women must agree to avoid pregnancy by not having sex or by using reliable birth control for 24 hours after the Flortaucipir injection.
  • Have taken part in a trial of a study drug or device in the 30 days before joining.
  • Take part in another drug or device study before finishing this study.
  • Have taken part in research using radioactive materials now or in the past 12 months if the total yearly research radiation would exceed federal limits.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Male or female, any race * Age \> 18 years * Participation in one of the ongoing projects affiliated with the Knight ADRC at Washington University and referred by the MAP staff and a Washington University physician. * Normal cognition or early-stage symptomatic AD * Willing and able to undergo study procedures. * Capacity to give informed consent and follow study procedures Exclusion Criteria: * Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., participants with severe chronic back pain might not be able to lie still during the scanning procedures); * Has hypersensitivity to either AV-1451 or PIB or any of its excipients; * Contraindications to PET, CT or MRI (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate; * Severe claustrophobia; * Currently pregnant or breast-feeding. Women must agree to avoid becoming pregnant and must agree to refrain from sexual activity or to use reliable contraceptive methods for 24 hours following administration of Flortaucipir injection; * Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment; * Must not participate in another drug or device study prior to the end of this study participation; * Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1

Study sites (1)

MO